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Chronic kidney disease is a devastating condition that,
according to 2008 data, affects 33 million Americans, or
16% of the United States population, with diabetes mellitus
replacing hypertension as the most frequent etiology. Par-
alleling the increase in chronic kidney disease is the number
of patients requiring vascular access for hemodialysis.1 In
2009, the incidence of new patients per year of hemodial-
ysis in the United States wasw106,000 and the prevalence
was >370,000.1
Since the introduction of the arteriovenous (AV) ﬁstula
in 1966 by Brescia and Cimino et al, vascular access proce-
dures have become one of the most frequent operations in
the United States. It is estimated that >500,000 vascular
access surgeries (including revisions) are being performed
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Center for Medicare and Medicaid Services (CMS)
spending, with the total 2009 Medicare expenditure for
hemodialysis patients >$20 billion.1
After the release of Kidney Disease Outcome Quality
Initiative (KDOQI) guidelines3 recommending AV ﬁstula
as the preferred vascular access for most patients and adop-
tion of the Fistula First Breakthrough Initiative (FFBI),
formerly known as the National Vascular Access Improve-
ment Initiative,4 the number of AV ﬁstulas in prevalent
hemodialysis patients increased from 38.6% in 2003 to
55% in 2007, whereas AV graft use decreased from
42.9% to 27.2%.1 An analysis of vascular access data from
the 2008 end-stage renal disease (ESRD) clinical perfor-
mance project indicates that w41% of incident patients
and 49% of all patients were dialyzed with an AV ﬁstula
during their last dialysis session.5 The ﬁrst network to
achieve the ﬁstula-ﬁrst goal was the Northwest Renal
Network, which as of August 2010, achieved an AV ﬁstula
rate of 67.7%.6 Although the incidence of ﬁstula placement
has increased, the need for immediate vascular access
through a central venous catheter (CVC) during this
same time period changed only slightly, from 18.5% to
17.7%.1
The KDOQI and FFBI guidelines rightly promote the
increased use of autogenous vascular access because of
superior patency rates and lower complication rates than
grafts once the access is established.7 After all, we ﬁrst
established this concept 3 decades ago.8 Yet many patients
do not have suitable venous anatomy to support an AV
ﬁstula, with the contemporary result that >50% of AV
ﬁstulas fail to attain suitability for hemodialysis.9 In short,
half of all AV ﬁstula operations performed nationwide
today fail.
In this discussion, we will point out the rationale for
appropriate, selective use of AV grafts and also show where
the results of AV ﬁstula must be critically analyzed. Our
central point will not be to prove that grafts are superior
but that they have an important role in those carefully
selected patients in whom an AV ﬁstula simply cannot be
constructed successfully. Access-related morbidity remains
the major impediment to full rehabilitation of the long-539
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ation of individual circumstances in deciding on the best
operation, including anatomy, patient age, avoidance of
CVCs, and anticipated time to begin dialysis. Advocacy
for AV ﬁstula must not replace scholarship.
Acknowledged advantages of AV ﬁstulas.
Compared with AV grafts and catheters, the rate of infec-
tion remains lowest with AV ﬁstulas, at 0.18 per patient-
year vs 0.39 for AV grafts and 1.45 for catheters.1 Once
established, AV ﬁstulas also have longer primary patency
rates than prosthetic access (Table I). Seven of the 11
studies cited in Table I show signiﬁcantly higher primary
patency for AV ﬁstulas, although not necessarily functional
patency. Reviews and meta-analyses comparing AV ﬁstulas
with prosthetic access have been limited by few prospective
study designs; however, secondary patency rates of AV
grafts are similar or close to those of AV ﬁstulas (Table I).
In fact eight of the 11 studies report no signiﬁcant differ-
ence in secondary patency between AV ﬁstulas and AV
grafts.
Challenges of AV ﬁstulas for hemodialysis. High
initial or early failure of AV ﬁstulas to function is a major
concern that often leads to prolonged wait during attempts
at balloon-assisted maturation.22 Rates of initial or early
failure (nonfunction) range between 20% and 60%.9,23,24
Early failure of AV ﬁstulas can be deﬁned as those ﬁstulas
that do not develop sufﬁciently to deliver adequate ﬂow
rates necessary for dialysis.24 Primary failure is often due to
inadequate maturation or thrombosis and unusually due to
ischemia or infection.24 A recent prospective, multicenter
study evaluating 491 AV ﬁstulas placed in 395 patients
concluded that the marked difference between AV ﬁstula
patency and functional patency rates may be explained by
high early failure rates.24 Dember et al9 conducted a large
multicenter trial involving 877 participants and in the
Journal of the American Medical Association reported an
astounding failure rate of AV ﬁstulas to function satisfac-
torily for dialysis in 460 of 758 patients (60.7%). This
inevitably leads to an increase in CVC dependence.
Given that ﬁndings reported in the literature often
convey implications for policy recommendations, it is
important that limitations pertaining to selection bias be
addressed. Speciﬁcally, selection bias may present in two
forms: (1) in choosing speciﬁc outcomes to report, and
(2) in choosing patients based on their potential to yield
desired outcomes. With regard to the former, numerous
studies set as their inclusion criteria only ﬁstulas or grafts
that are effectively cannulated.25 This, in effect, may
make outcomes of ﬁstulas appear more favorable because
early failures are excluded from analyses. Selection bias
also affects patient reporting; for example, an association
of lower prevalence of ﬁstulas has been shown for female
sex, black race, obesity, increased age, and peripheral
vascular disease.26 Studies concluding that a ﬁstula-ﬁrst
approach should be used for all patients must be critically
appraised for the presence of patients who have these
factors associated with high primary failure rates. Universal
endorsement of a ﬁstula-ﬁrst approach for all patients maynot be in the best interest of patients who may in fact
beneﬁt from a selective use of graft for access. As Allon
et al25 stated in 2008 in the Journal of the American Society
of Nephrology, “Whereas a ﬁstula may be the ideal access
choice in a young white man without cardiovascular
morbidity, it may be a poor choice in an older black woman
with cardiovascular morbidity.”
Individual considerations. “Fistula ﬁrst” is certainly
not for everyone. Recognizing the limits of autogenous
constructions, nephrologists have identiﬁed patients likely
to have AV ﬁstulas that would fail to mature.27 Speciﬁc
patient characteristics and risk factors predictive of matu-
ration failure in AV ﬁstulas included increased age,
peripheral vascular disease, coronary artery disease, race,
and diabetes.24,27 The inﬂuence of these factors on high
primary failure rates should be taken into consideration
when deciding on an initial choice of hemodialysis access.
We believe that each individual should be evaluated
critically for the best functional access. Our analysis shows
there are circumstances in which an AV graft would be ﬁrst
choice. Table II articulates those clinical situations. Huber
et al16 suggests that patency is only one of the several deter-
minants affecting the choice of the most appropriate access
site. These additional factors potentially include life expec-
tancy, patient preference, and number of revisions to main-
tain access patency, the length of time that temporary
catheters are required, and the time until access is
sufﬁciently developed for cannulation.16 Conservation of
proximal access sites for future use is of minimal impor-
tance for the ESRD patient with a limited life expectancy.
Letourneau et al28 reported that >50% of patients aged
>75 years died <2 years after starting dialysis, with
a mean survival of 31 months, and Joly et al29 found that
the median survival of octogenarians undergoing dialysis
was 28 months. In this population, the superiority of dial-
ysis quality as well as the lower rate of graft thrombosis in
the patient aged >65 years makes a graft a good alternative
to an AV ﬁstula.30
Recent trends in hemodialysis include an increase in the
elderly population requiring dialysis, the prevalence of dia-
betes, and cardiovascular comorbidities.31 Each of these
independent risk factors can affect the function of a dialysis
access. Atherosclerosis in the diabetic patient affecting fore-
arm arteries results in decreased inﬂow through the ﬁstula.
The fragile, thin-walled veins of the older patient often do
not become arterialized enough to withstand repeated
puncture. In the patient aged >85 years, the limited life
expectancy with ESRD may not justify an access any
more complex than a cuffed catheter.
Advantages of prosthetic grafts for hemodialysis.
One of the major advantages of an AV graft is provision of
high ﬂow rates preferred by nephrologists for efﬁcient dial-
ysis.12 When no veins remain for outﬂow in the forearm or
antecubital fossa, the brachioaxillary interposition AV graft
can provide early access without the uncertainty, avoiding
a wait that can be as long as 6 months for a transposed basilic
vein AV ﬁstula to mature.32 The 2008 Journal of Vascular
Surgery guidelines by Sidawy et al33 recommend using an
Table I. Primary and secondary patency rates in arteriovenous ﬁstulas (AVFs) and arteriovenous grafts (AVGs) reported
(1997-2011)
First author (year) Study type Access type
Initial
sample size,
No.
Time to
follow-up,
months
Primary patency Secondary patency
AVF vs AVG, % AVF vs AVG, %
Hodges11 (1997) Retrospective Autogenous 87 12 43 vs 41 (P < .7) 46 vs 59 (P ¼ .07)
PTFE 236
Matsuura12 (1998) Retrospective Autogenous 30 24 70 vs 46 (P ¼ .023) 70 vs 51 (P ¼ .020)
PTFE 68
Kalman13 (1999) Prospective Autogenous 235 24 54 vs 18 (P < .001) 70 vs 60 (P ¼ .331)
PTFE 231
Gibson14 (2001) Retrospective Autogenous 123 12 56 vs 36 (P ¼ .001) 72 vs 58 (P ¼ .003)
Prosthetic 85
Gibson15 (2001) Retrospective Autogenous
(simple)
492 12 56.1 vs 38.2 (P < .001) 73.2 vs 71.8 (P ¼ .24)
Prosthetic 1574 24 39.8 vs 24.6 (P < .001) 64.2 vs 59.5 (P ¼ .24)
Huber16 (2003) Systematic
review
Autogenous 1849 6 72 vs 58 (P < .05) 86 vs 76 (P < .05)
PTFE 1245 18 51 vs 33 (P < .05) 77 vs 55 (P < .05)
Weale17 (2007) Retrospective Autogenous 71 12 45.3 vs 56.4 53.6 vs 61.7
PTFE 114 24 40.0 vs 43.2 50.9 vs 41.1
(overall P ¼ .579) (overall P ¼ .868)
Kakkos18 (2008) Prospective Autogenous 41 12 46 vs 50 (P ¼ .62) 88 vs 81 (P ¼ .31)
Prosthetic 76 18 31 vs 26 (P ¼ .62) 84 vs 78 (P ¼ .31)
Keuter19 (2008) Randomized
trial
Autogenous 50 12 46 vs 22 (P ¼ .005) 89 vs 85 (P ¼ .532)
PTFE 51
Sala20 (2011) Retrospective Autogenous 36 1 93.5 vs 80.6 93.5 vs 80.6
PTFE 40 12 50.4 vs 64.3 50.4 vs 67.7
24 45.8 vs 46.2 45.8 vs 54.2
36 45.8 vs 31.6 45.8 vs 35.1
(overall P ¼ .719) (overall P ¼ .902)
Morosetti21 (2011) Randomized
trial
Autogenous 29 6 86 vs 55 86 vs 72
Graft 28 12 61 vs 32 76 vs 52
24 60 vs 21 66 vs 34
(overall P < .001) (overall P ¼ .08)
PTFE, Polytetraﬂuoroethylene.
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AV ﬁstula. If these vessels are not available for access, then
a graft is recommended.33 This has led to a subjective view
by the surgeon for what is considered suitable vessel size.
Many would agree that the diameter of the artery should be
at least 2 mm and the vein at least 3 mm. Studies arguing the
superiority of a transposed AV ﬁstula compared with a graft
likely select more favorable anatomy. Gibson et al15 deter-
mined that adequate “caliber” for vascular access of the
basilic vein was >4.0 mm. Selection bias is evident, in that
grafts are only placed in patients with poor anatomy for
autogenous vascular access. The transposed brachiobasilic
ﬁstula has certain advantages such as its large size and
a deeper position that prevents repetitive venipuncture.
Nevertheless, recent reports do not show a signiﬁcant
cumulative patency advantage over AV grafts.34,35 An AV
ﬁstula is certainly preferred when there is a likelihood of
functional success (perhaps 85%), but all too often, ﬁstulas
are constructed without this consideration.36
Vascular access by prosthetic grafts offers other advan-
tages, including earlier use, a larger surface area for cannu-
lation, and a lumen more amenable to thrombectomy. In
general, a standard AV ﬁstula will need a minimum of 4
to 6 weeks to properly mature. If the vein was not trans-
posed and a second operation is still necessary, anadditional month will be needed before cannulation for
dialysis. This period is further prolonged if the ﬁstula
requires a subsequent radiologic or surgical intervention
to achieve maturity (ie, balloon-assisted maturation).25 In
the United States, the median time from ﬁstula placement
to its ﬁrst cannulation is w3 months37 and longer for
a transposed ﬁstula. In contrast, AV grafts have been punc-
tured safely within the ﬁrst day of implantation.38 This
allows for immediate dialysis in critically ill patients with
no need for a CVC.
One of the additional advantages of placing an AV
ﬁstula is the decreased rate of infection compared with an
AV graft. Indeed, the rate of graft infection ranges from
6% to 9%, whereas AV ﬁstulas become infected only 1%
to 4% of the time. This advantage, however, is not as
straightforward as it may appear at ﬁrst glance. Almost all
patients commencing dialysis have CVCs that remain in
place until an AV ﬁstula is functional. On average, the liter-
ature quotes the rate of CVC infections at fewer than ﬁve
episodes per 1000 catheter-days; however, it may run as
high as ﬁve and one-half episodes per 1000 catheter-days
in dialysis patients.39 The risk of infection may be even
greater in the population who are elderly and diabetic.
Furthermore, a major underlying concern with chronic
CVC use is the rate of central venous stenosis with time.
Table II. Clinical situations in which an arteriovenous (AV) graft would be ﬁrst choice
d Brachial-axillary AV graft when a patient does not have anatomically suitable veins in the forearm or brachium.
d Forearm AV graft in a patient who requires urgent dialysis and cannot tolerate a prolonged central venous catheter.
d To avoid prolonged central venous catheterization in a patient who has ipsilateral axillosubclavian thrombosis and needs urgent access.
d If there is no site in the upper extremity for AV ﬁstula access.
d An AV graft in the end-stage renal disease patient with limited life expectancy.
d In a patient with clinical risk factors for AV ﬁstula failure that fulﬁll Lok’s criteria.16
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nents of the FFBI will often refer to the superior primary
patency rates of AV ﬁstulas compared with grafts. Early
patency rates at 1, 3, and 5 years have been reported as
two-times to four-times greater19,40,41 (Table I). As we
have pointed out, much of the literature reporting patency
rates is ﬂawed because of selection bias and removal of
patients with early ﬁstula failure. Also of note is that the
secondary patency rates between the two groups are
remarkably similar (Table I). Although grafts may need
more interventions after the initial construction, they have
greater salvage rates after thrombosis. In addition, there is
also no need for a CVC after salvage. Taken together, even if
more interventions are needed to maintain secondary
patency of the AV graft, which is now doubtful given the
increase in balloon-assisted maturation of AV ﬁstulas, the
difference may disappear if CVC insertion and removal to
support the AV ﬁstula is accounted for in the calculation.
Conclusions. The debate of whether to construct an
AV graft or AV ﬁstula has become somewhat moot.
Rather, it is imperative that each individual patient be crit-
ically analyzed before any vascular access procedure.
Further, maintenance of the vascular access site by a single
physician would offer continuity of care and a planned
program for future access. The KDOQI and FFBI have
made remarkable strides in improving awareness of ESRD
and the need for early referral for vascular access. However,
the current rate of nonfunctioning AV ﬁstulas, particularly
in the elderly population with multiple comorbidities, is
too high. Vascular access by a graft should not be aban-
doned because it may be the last option for some patients
and the best option in particular settings. Indeed, the
uncertainty in patency deﬁnitions, measurement of
outcomes, and paucity of prospective studies warrants
consideration of a randomized, prospective comparative
trial.
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POSITION: EXCELLENT LONG-TERM
OUTCOMES FOR AUTOGENOUS
ARTERIOVENOUS ACCESS JUSTIFY
AN AUTOGENOUS APPROACH FOR
MOST PATIENTS
William C. Jennings, MD, and John Blebea MD,
MBA, Tulsa, Okla
Although this review speciﬁcally focuses on the best
initial vascular access, it is worthwhile to brieﬂy reviewthe general consensus opinion of what constitutes the
preferred vascular access. Overall mortality, morbidity,
and cost considerations unquestionably favor autogenous
AV accesses (AV ﬁstulas). Catheter-based dialysis, particu-
larly long-term catheter use, is associated with the worst
outcomes in all of these categories, and prosthetic AV
accesses (AV grafts) are intermediate. Clearly, catheter
use should be minimized. There are, however, well-
documented differences between AV grafts and AV ﬁstulas
in associated morbidity, such as higher infection rates,
decreased access durability requiring interventions for
maintenance, shorter access life span, increased incidence
of access-related hand ischemia (ie, “steal”), and increased
mortality rates and cost for AV grafts.
AV grafts have a signiﬁcantly higher rate of infection
than AV ﬁstulas and, when infection develops, are more
likely to result in greater morbidity, require surgical
removal of the prosthetic conduit, and hospitalization.1-4
AV grafts are less durable than AV ﬁstulas and are more
likely to need intervention or surgical revision to maintain
patency and function.1-7 These differences in morbidity
and patency are reﬂected in the higher cost for patients
using AV grafts for dialysis access.
Overall mortality rates associatedwith vascular access are
highest for catheter-based dialysis, whereas AV grafts had
intermediate risk, and AV ﬁstulas the lowest risk.8,9 Astor
et al10 found annual mortality rates were 16% for catheter
patients, 14% forAVgrafts, and 12% forAV ﬁstula patients.10
An analysis of Medicare claims data for infectious mortality
by the 2010 Renal Report found antibiotic use among
patients who died in the hospital with a catheter or AV graft
reached 19% and 18%, respectively. Claims in the hospital
for patients with AV ﬁstulas were much lower, at only 9%.11
Patients with chronic kidney disease comprise only 7%
of the total population, but their care accounts for 22% of
all Medicare spending. Currently, w400,000 patients in
the United States receive renal replacement therapy by
hemodialysis.12,13 Total Medicare expenses were nearly
$454 billion in 2008, with end-stage renal disease costs
reaching $27 billion and hemodialysis expenses of $20
billion. The 2010 Renal Data Report found the per person
per year cost for vascular access events were highest for
patients with AV grafts, reaching $8683, whereas catheters
were the second most expensive at $6402. Access costs for
patients with an AV ﬁstula, in contrast, were only $3480,
60% lower than those for AV graft patients. Per person
per year total costs were greatest for patients with a catheter,
at $90,110, and AV grafts were $79,337. Overall costs for
patients with an AV ﬁstula were 28% and 18% lower,
respectively, at $64,701. The most common vascular access
event in 2010 was replacement of a current access with
a catheter, with 0.86 of these events per year for patients
already using a catheter, and 0.24 and 0.13, respectively,
for patients with an AV graft or an AV ﬁstula.10
Vascular access in the United States. The Dialysis
Outcomes and Practice Pattern Study (DOPPS) in 2002
demonstrated a great disparity among vascular access
patterns and outcomes between the United States and
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National Kidney Foundation-Kidney Disease Outcomes
Quality Initiative (KDOQI), the CMS-sponsored National
Vascular Access Improvement Initiative/Fistula First
Breakthrough Initiative (FFBI), and the Society for
Vascular Surgery (SVS) Clinical Practice Guidelines for the
Surgical Placement and Maintenance of Arteriovenous
Hemodialysis Access.1-3 All endorse use of an autogenous
access whenever possible. The groundbreaking KDOQI
Guidelines covered all aspects of dialysis care and catego-
rized vascular access options into three basic surgical AVF
divisions: radial-cephalic, brachial-cephalic, and brachial-
basilic vein transposition. FFBI and the SVS guidelines
extensively reviewed the many speciﬁc surgical options for
creating and maintaining a successful access, further cate-
gorizing, from simple to complex, the numerous options
for construction of functional AV ﬁstulas.
The initial KDOQI and FFBI improvement goal in the
United States was set for an AV ﬁstula prevalence rate of
40%.1,2 The emphasis on education and changing practice
patterns led to reaching the goal before the target date, and
the FFBI was initiated, with both organizations increasing
the AV ﬁstula goal to 66%. Vascular access surgeons in the
United States are well on the way to meeting this higher
goal (Fig). Overall and long-term catheter rates (catheters
present >90 days) have improved. AV graft rates in the
United States have plummeted as AV ﬁstula rates have
steadily increased. This experience has dramatically
exceeded the expectations of many physicians in the United
States who believed that even the initial goal of 40% AV
ﬁstulas would be impossible to reach. These data show
that functional AV ﬁstulas are feasible in most patients
and that the rates of improvement suggest more progress
can be expected. Several authors have reported establishing
a successful autogenous vascular access for nearly all
patients.15-17
Much of our vascular access practice is composed of
complex patients referred from other regions and states.
In a previous report of our access experience in 921 consec-
utive patients, an autogenous access was created in all
patients, with a cumulative (secondary) patency rate of
91% after 24months.16 Our primarymedical center’s outpa-
tient dialysis unit most recently reported monthly access
numbers were 81% AV ﬁstulas (4% awaiting catheter
removal), 4% AV grafts, 2% long-term catheters, and 13%
of patients new to dialysis awaiting referral, evaluation, or
scheduling for access creation. Our surgical group is respon-
sible for most but not all of the patients in this unit. We are
now focusing on strategies to improve the lag time to
construction of an AVF for these patients new to dialysis.
Grafts should be avoided in patients with AV ﬁstula
options. Past limitations used to justify lower AV ﬁstula
rates in the United States, based on patient characteristics,
surgeon training, experience, and available continuing
education, are no longer valid barriers to hemodialysis
patients beneﬁting from an autogenous vascular access.
Placing a forearm vascular access AV graft should espe-
cially be avoided, as recent guidelines have suggested.3 Ifa surgeon chooses to place an AV graft in the forearm,
a substantial outﬂow vein must be present to provide
adequate outﬂow and maintain AV graft patency. The
outﬂow vein must be the deep communicating (perfo-
rating) into the brachial system, the upper arm cephalic,
or the basilic vein. If one of these veins is large enough
to support AV graft patency, then that vein should be
adequate to construct a direct anastomosis to the proximal
radial artery or brachial artery and thereby establish an
autogenous access. This will result in a direct, simple AV
ﬁstula with the cephalic vein in the arm or a primary (or
staged) transposition into the median cubital/basilic vein
outﬂow system or the brachial vein.
Forearm AV grafts notoriously lead to the unfavorable
cycle of graft-catheter-graft, with each access failure leading
to a new prosthesis and destruction of venous sites other-
wise best used for autogenous access construction.18
Even when the initial surgeon feels he or she is construct-
ing a “ﬁrst step in a secondary AV ﬁstula,” later surgeons or
interventionalists will likely use balloon angioplasty, stent-
ing, or skip graft extensions in efforts to prolong the life
of the failing forearm AV graft, generally leading to only
brief periods of success. These stents and extended outﬂow
bypass segments result in critical loss of autogenous access
opportunities. The progressive frequency of these
secondary interventions increases the risk of communica-
tion failure between surgeon, nephrologist, and interven-
tionalist, resulting in these graft salvage procedures that
compromise the potential for a secondary AV ﬁstula
construction.18
AV grafts placed in the upper arm almost always use the
proximal basilic or axillary vein for outﬂow, with the likely
later progression to outﬂow vein stenosis and occlusion.
Repeated angioplasties, stents, and access failure leave the
entire extremity problematic for later vascular access possi-
bilities. Such patients are left with multiple failed and
embedded AV grafts, although ultrasound imaging may
reveal an adequate underlying vein suitable for a direct
AV ﬁstula or transposition. These old thrombosed AV
grafts complicate the establishment of a new AV ﬁstula.
Conﬂicting reports regarding outcomes of AV
ﬁstulas in the United States. Published experience with
autogenous vascular access varies widely throughout the
United States. Two major issues are generally noted
when objections arise to the published recommendations
for increasing the number of AV ﬁstulas: (1) the risk of
early AV ﬁstula thrombosis and (2) the potential for delay
in maturation, both of which are associated with prolonged
catheter dependency when they occur. Examples of the
wide variation in reported AVF outcomes include:
1. Radial-cephalic AV (RC-AV) ﬁstula reliability has
been questioned, with several older reports ﬁnding
up to 40% of these ﬁstulas have thrombosed or failed
to mature. Although an RC-AV ﬁstula remains our
ﬁrst choice for vascular access, only 10% of patients
seen in our complex access referral practice are
good candidates for this access site. We reported
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Fig. Prevalent vascular access reported for patients in the United States. AVF placed, Patients with an arteriovenous
ﬁstula in place; AVF in use, patients with an arteriovenous ﬁstula in use; AV graft, patients with an arteriovenous graft in
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patency after 2 years’ follow-up with RC-AV
ﬁstulas.19 This was accomplished when speciﬁc
preoperative criteria on physical and ultrasound
examinations were used to select individuals for this
procedure, creating a more proximal autogenous
access in patients where an RC-AV ﬁstula was likely
to fail. Other authors have reported similar success
rates with RC-AV ﬁstulas.20
2. Another example of variable reported outcomes is in
older patients, generally speciﬁed as individuals aged
>65 years. Some authors have reported higher failure
rates with autogenous access and prolonged delays in
maturation compared with younger patients and
suggest that AV graft placement might be a better
option. We found that targeting an upper arm
outﬂow vein for cannulation was a key element of
success in establishing a functional AV ﬁstula for
older patients.21 The skin overlying an upper cephalic
or transposed basilic vein has less chronic solar
damage and subsequent thinning, in addition to
more soft tissue coverage over the vein, making can-
nulation more reliable and available sooner.21 In
addition, we attempt whenever possible to construct
a moderate-ﬂow AV ﬁstula (500-750 mL/min as
measured by ultrasound) in older individuals based
on proximal radial artery inﬂow. By using such
a policy, AV ﬁstula patency rates were not different
in our elderly compared with our younger patient
populations. Functional access patency was >90% in
our patients aged >65 years at 2 years’ follow-up.
Other authors have found similar success with autog-
enous access in older patients.22 Outcomes in other
vascular access patient groups, such as adolescents
and children, have paralleled the change in AV ﬁstula
rates in adults, with multiple reports of nearly all
autogenous dialysis access in younger patients.233. A multicenter prospective randomized controlled
study designed to test clopidogrel in vascular access
patients found no beneﬁt in preventing early AV
ﬁstula failure. This trial found a surprisingly high
60% rate of AV ﬁstulas that failed to mature and be
suitable for dialysis.24 However, the intervention
rate was quite low in this study (an important
element for success), and the percentage of failed
AV ﬁstulas was among the highest reported in
a modern series, at odds with the current national
functional AVF rate of 62%.2,25 More than 70
surgeons participated in the trial, with a wide varia-
tion in the number of AV ﬁstulas contributed to
the study. These results differ dramatically from other
published vascular access outcomes, with early AV
ﬁstula failure rates of 5% to 15%.15-17,20 The wide
variation in autogenous access outcomes may be
related to surgical training, ultrasound skills, inter-
ventional capability, surgical experience, and case
volume. Proper initial access site selection is critical.
Avoiding early AV ﬁstula failure and minimizing
time to access maturation requires a careful preoper-
ative approach, keeping in mind the targeted cannu-
lation zone, ﬁnal access length, depth, diameter, and
ﬂow volume. Minimizing the risk of access-related
hand ischemia and arm swelling related to central
venous stenosis or occlusion, along with prompt
intervention when indicated, are also important parts
of the process. A complete working knowledge by
the surgeon of the many autogenous access options
available is a key element for success.
Keys to successful ultrasound mapping of AV
ﬁstulas. Ultrasound vessel mapping is a critical component
of a successful vascular access practice. Ultrasound in the
hands of the operating surgeon offers the greatest opportu-
nity for planning a functional vascular access in addition to
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measure and evaluate vessel size, depth, wall characteristics,
distensibility (compliance), and subtle areas of stenosis
leads to successful AV ﬁstula creation and prompt matu-
ration in most cases. With the ultrasound probe in hand,
the surgeon’s expectation of constructing a functional
ﬁstula is much higher, and access options become much
more obvious.26
Optimize potential AV ﬁstula options. The success-
ful vascular access surgeon has many options available,
including RC-AV ﬁstulas, antebrachial AV ﬁstulas, based
on the proximal radial artery inﬂow or brachial artery inﬂow,
and transposition procedures involving a basilic or brachial
vein.1,3,27-29 Lower extremity opportunities include
femoral and saphenous autogenous transpositions in addi-
tion to vein harvest and translocation to another extremity in
challenging access situations. However, femoral vein harvest
and transposition is a major undertaking and associated with
a higher risk of complications than seen with other autoge-
nous access procedures.30,31 Lower extremity vascular
access operations often require general anesthesia and are at
increased risk for infection, steal syndrome, compartment
syndrome, and delayed wound healing.
We occasionally use the saphenous vein for AV ﬁstula
revision or inﬂow proximalization but have often found it
problematic when used for cannulation sites. Distal and
direct (simple) AV ﬁstulas remain the ﬁrst recommendation
when physical and ultrasound examinations predict
success.19 When an RC-AV ﬁstula is not feasible, our
second choice and most common access operation is a prox-
imal radial artery AV ﬁstula using the many venous outﬂow
opportunities at this location.27 These moderate-ﬂow
ﬁstulas minimize the risk of access-related hand ische-
mia and are less likely to lead to venous hypertension
with arm swelling if central venous outﬂow obstruction
develops.32,33 In addition, the moderate ﬂow rate may be
less stressful for patients with congestive heart failure or
severe cardiac disease. We reported a cumulative functional
patency of 92% at 1 year with this AV ﬁstula procedure.27
Occasionally, patients with signiﬁcant ulnar artery occlusive
disease are evaluated where the radial artery is the only
signiﬁcant arterial supply to the hand. Using the proximal
ulnar artery for AV ﬁstula inﬂow is appropriate in such
patients, preserving ﬂow through the dominant radial
artery into the hand.
Basilic vein transposition procedures are best con-
structed, in our opinion, as primary operations when the
vein diameter is $4 mm.28 Basilic veins 2.5 to 4 mm in
diameter are often used in our practice in staged opera-
tions, with w4 weeks between the primary AV ﬁstula
construction and the later transposition. Staged basilic
vein transpositions have also been recommended by other
authors for pediatric and adult patients.34,35 Most brachial
vein transpositions should be completed in two stages.29
Many transpositions may be created using the proximal
radial artery for inﬂow.28,29
Direct (simple) AV ﬁstulas may be created in patients
with marginal outﬂow veins, anticipating that a balloonangioplasty procedure may be necessary for maturation.
These interventions generally result in a durable autogenous
access. Cannulation of most AV ﬁstulas is expected to be
initiated after 4 to 6 weeks. When a marginal ﬁstula is not
mature by that time, an ultrasound evaluation of the outﬂow
vein diameter and ﬂow volume measurements may suggest
that an additional short period of observation is justiﬁed if
ﬂow is approaching but has not yet reached 500 to 750
mL/min. Patients with marginal AV ﬁstulas may be moni-
tored longer if serial examinations and ultrasound imaging
show steady progress toward successful maturation.
However, if ﬂow is signiﬁcantly lower and the diameter
has not increased, the ﬁstula is not likely to mature, and
a ﬁstulogram with intervention should be considered. If
percutaneous intervention is unsuccessful, surgical revision
may be required. AV ﬁstulas in obese individualsmay require
additional procedures, such as a lipectomy or vein elevation,
for reliable cannulation.36 We generally wait 4 to 6 weeks
after the original access creation for these additional
procedures.
Coordination and communication of expectations with
the patient, the nephrologists, and the dialysis team leads to
timely maturation of a functional autogenous access in
most patients. Surgical follow-up is recommended for all
patients until the vascular access has been successfully used.
Maintaining the autogenous access. Maintenance of
an established autogenous access also plays an important
role in the long-term success of AV ﬁstulas. Skilled and
available interventional support plays a major role in
maturing marginal AV ﬁstulas and in the diagnosis and
treatment of a dysfunctional access. In some cases, the access
surgeon may be capable of providing all needed interven-
tions. If not, the surgeon and an experienced intervention-
alist must collaborate to achieve optimal patient outcomes.
Ultrasound imaging is complementary to contrast imaging
in detecting and localizing access problems, providing
functional physiologic information, and guiding the inter-
ventionalist in planning the procedure along with imme-
diate and subsequent monitoring of outcomes.
The timing and extent of balloon access maturation
(BAM) and surgical revision are not clearly deﬁned. Both
play important roles in vascular access maturation and
maintenance that vary with individual patients, surgeons,
and interventionalists. Similarly, the indications for use of
bare-metal and covered stents in an autogenous access
remain ill deﬁned. Placement of a covered stent in an AV
ﬁstula outﬂow vein for access salvage after BAM rupture
is increasingly common. Stenting of symptomatic central
venous lesions seems justiﬁed for recurrent failed angio-
plasty sites and for those lesions with immediate elastic
recoil. Asymptomatic central venous lesions should be left
undisturbed.
Successful resolution of access-related hand ischemia
and central venous outﬂow obstruction are examples of
autogenous access salvage opportunities that avoid access
ligation or abandonment. The most important element in
dealing with hand ischemia is prevention. AV grafts gener-
ally require higher blood ﬂow to maintain patency and carry
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Salvage of a dysfunctional AV ﬁstula in patients with hand
ischemia is feasible in most instances using options such as
precision banding over an angioplasty balloon, revision
using distal inﬂow, inﬂow proximalization, and distal revas-
cularization with interval ligation.38 Selection of the appro-
priate salvage procedure depends to a great degree on the
access ﬂow volume and the degree and location of arterial
disease within the affected limb. Preemptively establishing
a safe and functional AV ﬁstula in patients at high risk for
hand ischemia is possible using axillary artery inﬂow.39 In
patients with central venous obstruction and failed attempts
at central venous angioplasty, limiting the ﬂow through the
AV ﬁstula (eg, “banding”) has proven effective in maintain-
ing a functional access and effectively treating the arm
swelling in most patients.40
Conclusions. Surgical vascular access planning and
postoperative maintenance are tied to each individual
patient’s unique status and circumstance. Some of these
situations may be quite complex and challenging. The
access surgeon’s training, skill, and experience with all
autogenous access options will allow most patients to
have a successful AV ﬁstula established and maintained.
Although our practice has been to create an AV ﬁstula as
the initial procedure in each patient, best practice patterns
for each individual surgeon will vary based on training,
experience, technical skills, availability of interventional
support, ultrasound skills, dialysis center proﬁciency, and
speciﬁc patient clinical and anatomic opportunities. With
the proliferation of national and regional vascular access
educational opportunities, a goal of establishing and main-
taining an autogenous vascular access for most patients is
attainable and should be vigorously pursued.REFERENCES
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SUMMARY
Thomas S. Huber, MD, PhD, Gainesville, Fla
The role of prosthetic AV hemodialysis accesses (AV
grafts) in the current era of the Kidney Disease Outcome
Quality Initiative and the Fistula First Breakthrough Initia-
tive remains unresolved. As a direct result of these initia-
tives, a tremendous amount of pressure has been placed
on access surgeons to create autogenous AV accesses (AV
ﬁstulas), with a national target rate of 66% (prevalence).
Indeed, the prevalence of AV ﬁstulas and, perhaps more
importantly, the prevalence of central venous dialysis cath-
eters, have become markers for qualitydor lack thereof in
the cases of the cathetersdamong dialysis units. It is
unclear whether this AV ﬁstula target is realistic or appro-
priate, and the anecdotal impression has been that the
increased emphasis on AV ﬁstulas has inadvertently resulted
in an increased failure-to-mature rate and a prolonged
dependence on dialysis catheters. These concerns are
underscored by the 61% AV ﬁstula failure-to-mature rate
reported by the Dialysis Access Consortium from their
National Institution of Health, randomized, controlled
trial examining the role of clopidogrel.1
The data largely support the superiority of AV ﬁstulas
over AV grafts in terms of almost every outcome measure,including patency, morbidity, mortality, and cost.
However, the choice of permanent access conﬁgurations
may not be quite as clearcut or black-and-white as the
initiatives suggest. As Dr Wilson and colleagues point
out, appropriate comparison of the patency rates mandates
inclusion of all accesses that fail to mature, not just those
that are successfully cannulated. Accurate patency assess-
ment also mandates comparing comparable patient
cohorts, including those deemed high risk for failure after
both AV ﬁstula and graft creation, including elderly
patients, diabetic patients, women, and amputees. Simi-
larly, the appropriate comparison of the infectious compli-
cation rates likely mandates including the catheter-related
infections incurred during the ﬁstula maturation period
that frequently extends up to 6 months, again potentially
diluting or reducing the perceived beneﬁt of AV ﬁstulas.
Lastly, AV grafts have several relative advantages over AV
ﬁstulas, including an essentially unlimited supply, a shorter
maturation period, increased surface area for cannulation,
and greater ease of cannulation.
The debate about the role of AV grafts relative to AV
ﬁstulas may be somewhat artiﬁcial or moot, as suggested
by both Drs Jennings and Wilson. AV ﬁstulas and grafts
should be viewed as alternative options for providing effec-
tive, long-term hemodialysis. A mature AV ﬁstula is the
ideal choice for most patients and, fortunately, an AV
ﬁstula can usually be created or successfully achieved in
most patients, as emphasized in the debate. However,
AV grafts are a very acceptable alternative that may be
more appropriate for certain subsets of patients. The
current challenge is to select the most appropriate access
type or conﬁguration for a speciﬁc patient to ensure a func-
tional access while minimizing morbidity. It is the hope
that the results of the Hemodialysis Fistula Maturation
study, a prospective National Institutes of Health-funded
observation study of ﬁstula maturation, will help reﬁne
the clinical decision making for dialysis access, comple-
menting the adverse ﬁndings from its predecessor, the Dial-
ysis Access Consortium. However, it is important to
emphasize that maintaining permanent hemodialysis access
is a difﬁcult problem that requires committed providers and
a lifelong plan.REFERENCE
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